Trajenta Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Linagliptin

Indications/Uses

Adjunct to diet & exercise to improve glycemic control in adults w/ type 2 DM.

Click to view Trajenta detailed prescribing information

Dosage/Direction for Use

Adult 5 mg once daily.

Click to view Trajenta detailed prescribing information

Overdosage

View Trajenta overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

Click to view Trajenta detailed prescribing information

Special Precautions

Not to be used in patients w/ type 1 diabetes or for diabetic ketoacidosis. Possible hypoglycaemia when used concomitantly w/ sulphonylurea or insulin; may consider to reduce dose of sulphonylurea or insulin. Discontinue use if bullous pemphigoid is suspected. Possible acute pancreatitis; promptly discontinue use if pancreatitis is suspected. Possible dizziness may affect ability to drive or operate machinery. Avoid use during pregnancy. Lactation. Not recommended in childn & adolescents. Elderly >75 yr.

Click to view Trajenta detailed prescribing information

Use In Pregnancy & Lactation

Click to view Trajenta detailed prescribing information

Adverse Reactions

Nasopharyngitis; hypersensitivity, angioedema, urticaria; hypoglycaemia (in combination w/ metformin + sulphonylurea), hypertriglyceridaemia (in combination w/ sulphonylurea), hyperlipidaemia (in combination w/ pioglitazone); cough; pancreatitis, constipation (in combination w/ insulin), mouth ulceration; rash, bullous pemphigoid; increased wt (in combination w/ pioglitazone), lipase & amylase.

Click to view Trajenta detailed prescribing information

Drug Interactions

Decreased steady-state AUC, C_max & dipeptidyl peptidase-4 inhibition at trough w/ rifampicin; closely monitor glucose & consider alternative treatments in cases of insufficient efficacy. Increased plasma AUC & C_max of simvastatin.

Click to view Trajenta detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Trajenta detailed prescribing information

Storage

View Trajenta storage conditions for details to ensure optimal shelf-life.

Description

View Trajenta description for details of the chemical structure and excipients (inactive components).

Action

View Trajenta mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidiabetic Agents

ATC Classification

A10BH05 - linagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.

Regulatory Classification

POM

Presentation/Packing

Form

Trajenta FC tab 5 mg

Packing/Price

30's

Trajenta

linagliptin

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH